Company
Headquarters: Westlake Village, CA, United States
Employees: 23
CEO: Mr. Thomas Zindrick J.D.
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $170,000 |
| EBITDA | $-23,666,000 |
| Gross Profit TTM | $0 |
| Profit Margin | 0.00% |
| Operating Margin | -14214.71% |
| Quarterly Revenue Growth | -100.00% |
GENELUX CORPORATION has the following listings and related stock indices.
Stock: NASDAQ: GNLX wb_incandescent